7-beta-alkyl Orvinol Analogs for Peripheral Opioid Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current analgesics for pain management often have limitations, including central side effects and poor potency when acting on peripheral opioid receptors, necessitating the development of compounds that effectively modulate opioid receptors for both central and peripheral pain relief without significant side effects.
Innovation Solution
Development of novel 7β-alkyl and 7β-methyl analogs of orvinols, which act as modulators of µ, δ, κ, and ORL-1 opioid receptors, offering agonist or antagonist activity to provide effective pain relief with reduced central side effects by targeting both central and peripheral opioid receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If centrally penetrating κ agonists are used to produce antinociceptive effects, then pain relief is improved, but sedative and psychotomimetic side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular characteristics (7β-alkyl substitution patterns) that enable selective interaction with peripheral opioid receptors. The structural modifications create localized chemical properties that favor peripheral receptor binding over central nervous system penetration, thereby achieving pain relief with reduced central side effects.
Solution Approach 2:
The invention utilizes parameter changes by systematically varying the alkyl substitution at the 7β-position of the orvinol core structure. By changing the size and nature of the alkyl group, the compounds achieve different balances between peripheral potency and central penetration, allowing optimization of the therapeutic window to maximize analgesia while minimizing sedation and psychotomimetic effects.
2Reliability
If opioid receptor agonists are designed to act on central receptors for effective pain relief, then analgesic potency is improved, but central side effects increase
Solution Approach 1:
The patent applies segmentation by separating the analgesic function from the central side effect production through peripheral restriction. The compounds are designed to act primarily on peripheral opioid receptors (including peripheral κ-opioid receptors) rather than crossing the blood-brain barrier to act on central receptors, thereby segmenting the therapeutic effect from the adverse effects.
Solution Approach 2:
The invention uses peripheral opioid receptors as intermediaries to achieve pain relief without direct central nervous system involvement. The compounds act on peripheral κ-opioid receptors and other opioid receptors in peripheral tissues, serving as intermediaries that transmit analgesic effects while blocking the pathway that would lead to central side effects.
3Object-affected harmful factors
If compounds are designed to act on peripheral opioid receptors to reduce central side effects, then central side effects are reduced, but analgesic potency may be compromised
Solution Approach 1:
The patent applies universality by designing compounds that can act on multiple opioid receptor types (κ, μ, and other opioid receptors) at peripheral sites. The 7β-alkyl orvinol compounds exhibit broad receptor profile activity, enabling them to engage various peripheral opioid receptors simultaneously, thereby maintaining robust analgesic potency through multiple mechanisms while remaining peripherally restricted.
Data Source
AI summary
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R1a, R1b, R1c, X, Y, Z, G, O, W1 and W2 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.